Commenting on the Scottish Government’s decision to establish a dedicated New Medicines Fund worth £40m, ABPI Scotland Director Andrew Powrie-Smith said:

“The ABPI welcomes the Scottish Government’s utilisation of industry’s PPRS payments to ensure Scottish patients have access to new medicines through the establishment of this fund . We firmly believe that it will have a positive impact on the lives of Scottish people. In the PPRS agreement, industry has agreed to do its part by keeping NHS expenditure on branded medicines across the UK flat for two years, with the industry underwriting any further expenditure by the NHS within agreed boundaries, and I am glad to see that the Scottish Government are leading the way in re-investing money from PPRS in new medicines. 

The ABPI is committed to continuing to work with the Scottish Government and all other stakeholders to ensure patients outcomes benefit from the better use of medicines”.

For more details, go to: http://www.abpi.org.uk/media-centre/newsreleases/2014/Pages/071014.aspx